Albuquerque Journal

Startups survived, some thrived in COVID

- BY KEVIN ROBINSON-AVILA JOURNAL STAFF WRITER

New Mexico’s startup activity may have been less publicly visible during the pandemic as companies and programs moved online, but local entreprene­urship remains alive and well, and some newly-launched businesses are thriving.

Among the pandemic standouts is Santa Fe-based Avisa Diagnostic­s Inc., which went public on the Canadian Securities Exchange in May after reaching an agreement last year with investment group Global Emerging Markets Limited to provide Avisa access to a $41 million line of equity if the company began trading publicly outside the U.S. Avisa went live on the CSE in mid-May through a merger with another publicly traded entity, Fogchain Corp.

Avisa, which launched in 2010, has developed a rapid breath test for bacterial pneumonia and other pulmonary infections based on technology it originally licensed from the University of New Mexico. It previously raised $16 million in private equity, including money from Santa Fe-based Sun Mountain Capital, which manages the New Mexico State Investment Council’s Co-Investment Fund for investment­s in local startups, giving the state a significan­t stake in Avisa’s future success.

Over the next three years, Avisa will draw down on GEM’s $41 million line of equity to finance further product developmen­t and clinical trials to win U.S. Food and Drug Administra­tion approval for its technology.

Another standout — biomedical startup Nature’s Toolbox, or NTxBio — received $5 million in Local Economic Developmen­t Act funding last fall to relocate this summer from Santa Fe to a 25,000-square-foot facility in Rio Rancho. The company, which raised $13 million in private equity last year just before the pandemic hit, has created novel technology to rapidly develop new vaccines and drugs based on processes originally licensed from Los Alamos National Laboratory.

The LEDA funding has allowed NTxBio to build out its new Rio Rancho facility into a high-tech research and manufactur­ing center for new pharmaceut­icals. The company, which launched in 2015, expects to hire 116 people over the next decade at an average annual salary of $74,000, representi­ng about $74.5 million in additional payroll over the next 10 years.

Many more startups also had noteworthy achievemen­ts during the pandemic, in particular, Parting Stone of Santa Fe and Albuquerqu­e-based BennuBio Inc., Build with Robots, and WaveFront Dynamics Inc.

 ?? COURTESY OF AVISA PHARMA ?? Avisa Diagnostic­s Senior Vice President for Product Developmen­t David Karshmer, left, and president and CEO David Joseph with the company’s measuremen­t device for respirator­y infections.
COURTESY OF AVISA PHARMA Avisa Diagnostic­s Senior Vice President for Product Developmen­t David Karshmer, left, and president and CEO David Joseph with the company’s measuremen­t device for respirator­y infections.

Newspapers in English

Newspapers from United States